PIH24 - Productivity Gains Associated with Treatment with Elagolix For Endometriosis-Associated Pain

Abstract

Examine the impact of elagolix, an oral gonadotropin-releasing hormone antagonist, on workplace productivity improvement among endometriosis patients. Two randomized, double-blind, phase III clinical trials (ELARIS EM-I and EM-II) compared elagolix 150 mg once daily (ELA QD) or elagolix 200 mg twice daily (ELA BID), respectively, to placebo in women with surgically-confirmed endometriosis and moderate to severe endometriosis-associated pain. Both trials included the Health-Related Productivity Questionnaire assessing hours lost in the workplace over the past week due to absenteeism and presenteeism. Changes from baseline in hours lost were examined at month 3 using ANCOVA. Total number of randomized patients was 872 in EM-I and 817 in EM-II. At 3 months in EM-I, least squares mean [LS mean; standard error (SE)] change from baseline revealed hours absent from work declined by 0.87 (0.28) for placebo vs 1.92 (0.33) for ELA QD (P=0.016) and vs 2.65 (0.34) for ELA BID (P<0.001). Hours lost to presenteeism declined from baseline by 6.23 (0.53) for placebo vs 7.24 (0.63) (P=0.219) for ELA QD and vs 9.16 (0.66) for ELA BID (P<0.001). Total hours lost declined by 7.00 (0.65) for placebo vs 9.20 (0.79) for ELA QD (P=0.032) and vs 11.90 (0.81) for ELA BID (P<0.001). Similarly, in EM-II at 3 months, hours absent from work declined by 0.76 (0.27) for placebo vs 1.43 (0.34) (P=0.121) for ELA QD and vs 2.17 (0.34) for ELA BID (P=0.001) while hours lost to presenteeism declined by 4.07 (0.63) for placebo vs 6.10 (0.80) for ELA QD (P=0.047) and vs 7.27 (0.80) for ELA BID (P=0.002). Total hours lost declined by 4.66 (0.71) for placebo vs 7.31 (0.89) for ELA QD (P=0.020) and vs 9.30 (0.89) for ELA BID (P<0.001). Elagolix treatment resulted in improved workplace productivity among endometriosis patients through reducing the numbers of work hours lost.